ATE334983T1 - Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit - Google Patents

Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit

Info

Publication number
ATE334983T1
ATE334983T1 AT03762050T AT03762050T ATE334983T1 AT E334983 T1 ATE334983 T1 AT E334983T1 AT 03762050 T AT03762050 T AT 03762050T AT 03762050 T AT03762050 T AT 03762050T AT E334983 T1 ATE334983 T1 AT E334983T1
Authority
AT
Austria
Prior art keywords
spiro
obesity
treatment
hormone receptor
substituted piperidine
Prior art date
Application number
AT03762050T
Other languages
English (en)
Inventor
Duane A Burnett
Wen-Lian Wu
Thavalakulam K Sasikumar
Martin S Domalski
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE334983T1 publication Critical patent/ATE334983T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03762050T 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit ATE334983T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27

Publications (1)

Publication Number Publication Date
ATE334983T1 true ATE334983T1 (de) 2006-08-15

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03762050T ATE334983T1 (de) 2002-06-27 2003-06-26 Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit

Country Status (15)

Country Link
US (1) US7109207B2 (de)
EP (1) EP1532147B1 (de)
JP (1) JP4522853B2 (de)
CN (1) CN100374440C (de)
AR (1) AR040344A1 (de)
AT (1) ATE334983T1 (de)
AU (1) AU2003258957A1 (de)
CA (1) CA2490531C (de)
DE (1) DE60307289T2 (de)
ES (1) ES2266861T3 (de)
HK (1) HK1071567A1 (de)
MX (1) MXPA05000185A (de)
PE (1) PE20040749A1 (de)
TW (1) TW200401777A (de)
WO (1) WO2004002987A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005519876A (ja) 2001-11-27 2005-07-07 メルク　エンド　カムパニー　インコーポレーテッド ２−アミノキノリン化合物
CA2515717A1 (en) 2003-02-10 2004-08-19 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
CN1777596A (zh) * 2003-02-28 2006-05-24 先灵公司 作为选择性mch受体拮抗剂用于治疗肥胖及相关病症的联芳基四氢异喹啉哌啶
MXPA06011265A (es) 2004-03-29 2006-12-15 Pfizer Compuestos propanamida alfa aril o heteroaril metil beta piperidino como antagonistas del receptor orl1.
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JPWO2006104136A1 (ja) * 2005-03-29 2008-09-11 萬有製薬株式会社 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
AU2007301126A1 (en) * 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
US10407428B2 (en) * 2014-11-21 2019-09-10 Esteve Pharmaceuticals, S.A. Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
AU769081B2 (en) 1999-08-26 2004-01-15 Bristol-Myers Squibb Company NPY antagonists: spiroisoquinolinone derivatives
EP1268000A4 (de) * 2000-03-23 2004-12-29 Merck & Co Inc Spiropiperidinderivate als melanocortin-rezeptor agonisten
EP1299362A4 (de) * 2000-07-05 2004-11-03 Synaptic Pharma Corp Selektive rezeptorantagonisten des melaninkonzentrierenden hormons-1 (mch1) und ihre anwendung

Also Published As

Publication number Publication date
CN1665812A (zh) 2005-09-07
JP2005535641A (ja) 2005-11-24
HK1071567A1 (en) 2005-07-22
DE60307289T2 (de) 2007-10-18
US20040024002A1 (en) 2004-02-05
AR040344A1 (es) 2005-03-30
US7109207B2 (en) 2006-09-19
EP1532147A1 (de) 2005-05-25
PE20040749A1 (es) 2004-10-23
TW200401777A (en) 2004-02-01
ES2266861T3 (es) 2007-03-01
CN100374440C (zh) 2008-03-12
EP1532147B1 (de) 2006-08-02
CA2490531A1 (en) 2004-01-08
DE60307289D1 (de) 2006-09-14
AU2003258957A1 (en) 2004-01-19
JP4522853B2 (ja) 2010-08-11
WO2004002987A1 (en) 2004-01-08
MXPA05000185A (es) 2005-04-08
CA2490531C (en) 2011-03-22

Similar Documents

Publication Publication Date Title
ATE334983T1 (de) Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit
DE60010722D1 (de) Dibenzopyrane als glucocorticoid-rezeptor-antagonisten für die behandlung von zuckerkrankheit
ATE374182T1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
ATE420083T1 (de) Harnstoff-derivate als vanilloid-rezeptor- antagonisten für die schmerzbehandlung
MX2007004306A (es) Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados.
ATE474577T1 (de) Bicyclische piperidin-derivate als melanocortin-4 rezeptor-agonisten
DE60312999D1 (de) Vorrichtung zum anbringen von nähten
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
ATE429226T1 (de) Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind
DE602007006019D1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
NO20053490D0 (no) Methods for prediciting therapeutic response to agents acting on the growth hormone receptor
DE60326788D1 (de) Zeitmessvorrichtung und Steuerungsverfahren für die Zeitmessvorrichtung
DE60302913D1 (de) Erweiterung des Befehlssatzes zum software-initiierten Vorausladen
ATE393766T1 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
ATE512959T1 (de) 2-substituierte benzimidazolpiperidinanaloga als selektive antagonisten des auf das melanin- konzentrierende hormon wirkenden rezeptors zur behandlung von obesitas und verwandten erkrankungen
ATE356016T1 (de) Rahmen für sessel von sesselliften
ATE335500T1 (de) Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose
DE602005014985D1 (de) Heterocyclylverbindungen als selektive antagonisten am rezeptor für das melaninkonzentrierende hormon zur behandlung von obesitas und verwandten erkrankungen
DE10314499B4 (de) Vorrichtung zum Drahtbonden
ITBZ20030057A1 (it) Procedimento e dispositivo per il trattamento dell'acqua
NO20025737D0 (no) Ultralyd triggering metode
AU2003262926A1 (en) Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
ITTV20020134A1 (it) Dispositivo di elettrostimolazione particolarmente per stimolazione neuromuscolare

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties